Another Infliximab Biosimilar On Horizon In India?
More competition appears to be in the wings for Remicade in India after the Russian firm Biocad’s biosimilar infliximab was endorsed in India by an expert panel, though there’s little clarity on launch specifics, at least for now.
You may also be interested in...
Sun’s Ilumya is available in the US and Europe, with China now on the launch radar as well. Scrip examines whether the firm’s home turf India should also be among the early markets for the novel psoriasis asset, amid pressure to maintain the 'price line'.
Two Years On The Market And Only A 7% Volume Share – J&J Numbers Reveal Infliximab Struggle For US Biosimilars
Value-wise, Johnson & Johnson’s sales of the Remicade original in the US fell by around a fifth last year with two biosimilars on the market, the originator has just reported. However, thanks in part to what it described as “increased discounts,” J&J was able to retain more than nine-tenths of the infliximab market by volume.
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.